Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUNFAT)

• Drug Name: Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1 Drug Info
• Synonyms: PMID25539043-Compound-WO2013122897Example51
• Cross-matching ID: TTD Drug ID: DMUNFAT

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.7 (SCN9A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEN-402	DMR69CG	Osteoarthritis	FA00-FA05	Phase 2	[2]
PF-05089771	DMD74BJ	Chronic pain	MG30	Phase 2	[3]
BIIB074	DMLV1ET	Bipolar disorder	6A60	Phase 2	[4]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[4]
BIIB095	DMUC6EP	Pain	MG30-MG3Z	Phase 1	[4]
GDC0310	DMUNFEP	Chronic pain	MG30	Phase 1	[5]
DSP-3905	DMYHU24	Neuropathic pain	8E43.0	Phase 1	[4]
PF-05241328	DM2NTBL	Pain	MG30-MG3Z	Phase 1	[6]
DWJ-208	DMQKDJZ	Cancer related pain	MG30	Phase 1	[4]
RG7893	DM1R4MQ	Pain	MG30-MG3Z	Phase 1	[7]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.5 (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mephenytoin	DM5UGDK	Epilepsy	8A60-8A68	Approved	[8]
Mexiletine	DMCTE9R	Ventricular tachycardia	BC71	Approved	[9]
Fosphenytoin	DMOX3LB	Epilepsy	8A60-8A68	Approved	[8]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[9]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[10]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[11]
Dyclonine	DMU6OFP	Pain	MG30-MG3Z	Approved	[12]
Moricizine	DMOMBJW	Arrhythmia	BC9Z	Approved	[13]
Ethotoin	DMXWOCP	Complex partial seizure	8A68.0	Approved	[14]
Prilocaine	DMI7DZ2	Pain	MG30-MG3Z	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A)	TTZOVE0	SCN5A_HUMAN	Blocker	[1]
Voltage-gated sodium channel alpha Nav1.7 (SCN9A)	TT4G2JS	SCN9A_HUMAN	Blocker	[1]

References

• [1] Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
• [2] Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
• [3] Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
• [4] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)
• [8] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [9] Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
• [10] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [11] Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
• [12] Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
• [13] From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
• [14] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.